24 Jun

What Analysts Recommend for Pfizer and Bristol-Myers Squibb

WRITTEN BY Margaret Patrick

The better pick?

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let’s take a closer look at each.

Analysts’ recommendations and target prices

Most analysts recommend “buy” for Pfizer and Bristol-Myers Squibb. Of the 16 analysts covering Pfizer, two recommend “strong buy,” seven recommend “buy,” six recommend “hold,” and one recommends “strong sell.” They increased their average target price from $44.14 in March to $44.36 in April, $45.08 in May, and to $45.57 in June, and their most recent target implies a 4.76% upside based on its June 19 closing price. Their highest and lowest targets are $53 and $36.

Of the 15 analysts covering Bristol-Myers Squibb, three recommend “strong buy,” four recommend “buy,” and eight recommend “hold.” They increased their average target price from $57 in March to $57.90 in April, but then reduced it to $56.33 in May and $56.30 in June, which implies a 15.82% upside from its June 19 price. Their highest and lowest targets are $70 and $48.

Stock price movement and valuation

Pfizer stock closed at $43.50 yesterday, 1% higher than its previous close, 21.27% higher than its 52-week low of $35.87, and 6.39% lower than its 52-week high of $46.47. The company’s market capitalization is $245.12 billion, and its PE, forward PE, PEG (PE-to-growth), PS (price-to-sales), PB (price-to-book), and PC (price-to-cash) ratios are 24.09x, 14.20x, 4.97x, 4.55x, 4.17x, and 21.10x, respectively.

Bristol-Myers Squibb closed at $48.61 yesterday, 1.72% higher than its previous close, 9.73% higher than its 52-week low of $44.30, and 23.68% lower than its 52-week high of $63.69. The company’s market capitalization is $79.43 billion, and its PE, forward PE, PEG, PS, PB, and PC ratios are 15.39x, 10.96x, 2.90x, 3.41x, 5.22x, and 9.06x, respectively. Pfizer has higher PE, forward PE, PEG, PS, and PC ratios than Bristol-Myers Squibb, but a lower PB ratio.

Latest articles

On November 14, The George Soros Fund Management LLC filed 13F. The firm's total market value was around $3.6 billion at the end of Q3 2019.

Tesla (TSLA) stock short sellers seem to be getting exasperated. Notably, Tesla stock has been the short sellers’ favorite.

In the week that ended on November 15, natural gas prices fell 3.5% and settled at 2.688 per MMBtu (million British thermal units).

The Dow Jones Index (DIA) and S&P 500 (SPY) are trading at record highs and on Friday the Dow Jones crossed the 28,000 level for the first time.

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.